Search

everythinglearnresearchcommunity

for

Search:↓

Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.

The most effective way to diagnose non-scarring hair loss is by transverse sectioning, and some cases, particularly in males with inflammation around hair follicles, might be curable.

The conclusion is that a new method could improve the identification of autoimmune targets in alopecia areata, despite some limitations.

Erdr1 could be a new marker for diagnosing hair loss.

A standard protocol for alopecia areata clinical trials was created to improve consistency and encourage more research.

Specific immune cells cause alopecia areata and blocking certain proteins can prevent it.

Dermoscopy helps diagnose different scalp conditions by showing unique signs for each disorder.

Alopecia Areata is an autoimmune condition causing hair loss, influenced by genetics, environment, and possibly improved by anti-MIF therapy, with many patients experiencing regrowth within a year.

Alopecia areata can regrow hair in a pattern similar to androgenetic alopecia.

Alopecia areata is unpredictable, with limited treatment effectiveness, especially in severe cases.

A woman with Kallman's syndrome also developed alopecia universalis, a condition not previously linked to Kallman's.

A rare case showed hair regrowth after chemotherapy for thymoma, suggesting a link between alopecia areata and thymoma.

Microneedles combined with conventional therapies show promise in treating alopecia areata.

COVID-19 vaccines have been linked to an increase in hair loss conditions.

In Germany, alopecia areata is common and often occurs with skin conditions like eczema and psoriasis, affecting women slightly more and varying by region.

Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.

Traditional treatment for pediatric alopecia areata is most effective and should be first choice.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.

Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.

Certain genetic variants linked to immune response increase the risk of alopecia areata in Taiwanese people.

Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

Scalp rolling might help regrow hair in people with a hair loss condition called Alopecia Areata.

Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.

Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.

People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.

People with Alopecia Areata are more likely to have autoimmune diseases, inflammatory diseases, and mental health issues like anxiety and depression.

Younger patients and those with more hair loss are less likely to benefit from oral steroid treatment for hair loss, and low vitamin D may predict relapse.

New treatments for hair loss from alopecia areata may include targeting immune cells, using stem cells, balancing gut bacteria, applying fatty acids, and using JAK inhibitors.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.